47 filings
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
3 May 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:27pm
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
3 May 24
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
7:01am
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
17 Apr 24
Entry into a Material Definitive Agreement
4:06pm
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
15 Apr 24
Regulation FD Disclosure
4:16pm
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
29 Mar 24
AEON Biopharma Announces Redemption of Public Warrants
4:16pm
8-K
ox4irep1rgi 3854hd
29 Mar 24
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
3:46pm
8-K
hu7h f51rkuyyhdicw
28 Mar 24
Entry into a Material Definitive Agreement
4:06pm
8-K
27ibl9 2zlm7elfmd
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
nu4jf2
16 Feb 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:10pm
8-K
sxp7yods7ozrg
13 Nov 23
AEON Biopharma Reports Third Quarter 2023 Financial Results
9:00am
8-K
r3l9797eu
19 Oct 23
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
4:23pm
8-K
chtzlj8e
2 Oct 23
Changes in Registrant's Certifying Accountant
5:06pm
8-K/A
bofk7c1rtu37dgxi
11 Aug 23
Financial Statements and Exhibits
9:12pm
8-K
b1aug081f80 uom9i
27 Jul 23
Index to Financial Statements
5:28pm
8-K
32r84mx
24 Jul 23
Corporate Presentation July 2023
6:43am
8-K
ff7wla fmww5lc8oct
17 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:18pm
8-K
i30po12ppo vexuael5
11 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:09pm
8-K
m5xe4jv
5 Jul 23
Departure of Directors or Certain Officers
4:51pm
8-K
9w2z83
30 Jun 23
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
8:26am
8-K
2500enm2
29 Jun 23
Entry into a Material Definitive Agreement
9:18pm